PMEF
PRAX icon

Point72 Middle East FZE’s Praxis Precision Medicines PRAX Stock Holding History

Point72 Middle East FZE’s Portfolio PRAX Stock Details PRAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-151
Closed -$5.4K – 2080
2022
Q4 		$5.4K Buy
+151
New +$4.71K ﹤0.01% 1775

Other funds holding PRAX

VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TLP
Tri Locum Partners New York $713M AUM 68.92% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Point72 Middle East FZE's PRAX Position: Q1 2023 in Review

Point72 Middle East FZE sold out of Praxis Precision Medicines (PRAX) in Q1 2023, closing a stake of 151 shares — an estimated $5.4K sold.

Point72 Middle East FZE first reported a position in PRAX in Q4 2022 and held it in 1 quarter. The position peaked at $5.4K in Q4 2022. 86 funds tracked by Wall St. Rank hold PRAX as of Q1 2023.

  • Point72 Middle East FZE reported no remaining Praxis Precision Medicines position as of Q1 2023 after selling out during the quarter.
  • Point72 Middle East FZE sold 151 Praxis Precision Medicines shares in Q1 2023, an estimated $5.4K.
  • Point72 Middle East FZE first reported a position in Praxis Precision Medicines in Q4 2022 and held it in 1 quarter.
  • Point72 Middle East FZE's Praxis Precision Medicines position peaked at $5.4K in Q4 2022.
  • 86 funds tracked by Wall St. Rank held Praxis Precision Medicines as of Q1 2023.

Based on Point72 Middle East FZE's 13F filing for Q1 2023, filed 15 May 2023.